Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on May 1, 2017. The report discloses a significant corporate development regarding a new commercial agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a disclosure of a contractual event rather than a financial performance report.
Material Changes
The primary material event reported is the signing of a new five-year agreement to supply pharmaceuticals to Express Scripts Holding Company. This agreement represents a significant expansion or renewal of the Company's distribution relationships.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the agreement. The filing explicitly states that the information contained in the report and the attached news release (Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference in other filings, except as expressly set forth by specific reference. No specific risks, contingencies, or unusual items are detailed within the text of this 8-K form itself.
Investor Verification Checklist
- Verify the specific financial terms and volume commitments of the five-year agreement with Express Scripts Holding Company in the attached news release (Exhibit 99.1).
- Confirm the impact of this agreement on the Company's future revenue guidance and market share in the pharmaceutical distribution sector.
- Review subsequent filings to determine if this agreement was incorporated by reference into other regulatory documents.